June 20, 2024
4 min watch
Save
VIDEO: Strong results for asciminib in chronic myelogenous leukemia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to chronic myelogenous leukemia, presented at ASCO Annual Meeting.
McMahon, an assistant professor at University of Colorado School of Medicine, highlighted the study, which examined asciminib (Scemblix, Novartis) versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML.
“Overall, asciminib had higher rates of [mismatch repair] compared to the current front-line standard TKIs, and it also appeared to have a more favorable tolerability,” McMahon said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
McMahon reports receiving institutional funding from Syndax and Syros, and serving on a safety monitoring committee for Kura Oncology.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.